This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential
Cellular and Molecular Life Sciences Open Access 29 September 2022
-
Therapeutic effect of various ginsenosides on rheumatoid arthritis
BMC Complementary Medicine and Therapies Open Access 25 May 2021
-
A shedding soluble form of interleukin-17 receptor D exacerbates collagen-induced arthritis through facilitating TNF-α-dependent receptor clustering
Cellular & Molecular Immunology Open Access 22 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D. & Wigzell, H. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 72, 3632–3636 (1982).
Janossy, G. et al. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2, 839–842 (1981).
Bottazzo, G.F., Pujol-Borrell, R., Hanafusa, T. & Feldmann, M. Role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet 2, 1115–1119 (1983).
Taniguchi, T. et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305–310 (1983).
Pennica, D. et al. Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 312, 724–729 (1984).
Yasukawa, L. et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6 gene). EMBO J. 6, 2939–2945 (1987).
Feldmann, M., Brennan, F.M. & Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440 (1996).
Buchan, G. et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73, 449–455 (1988).
Brennan, F.M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin- 1 production in rheumatoid arthritis. Lancet 2, 244–247 (1989).
Haworth, C. et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 21, 2575–2579 (1991).
Fong, Y. et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170, 1627–1633 (1989).
Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125–1132 (1991).
Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784–9788 (1992).
Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031 (1991).
Tracey, K.J. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662–664 (1987).
Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681–1690 (1993).
Elliott, M.J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127 (1994).
Elliott, M.J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110 (1994).
Maini, R.N. et al. Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNFα monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563 (1998).
Williams, R.O., Mason, L.J., Feldmann, M. & Maini, R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762–2766 (1994).
Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).
Weinblatt, M.E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibodiy, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35–45 (2003).
ATTRACT Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343, 1594–1602 (2000).
ATTRACT Study Group. Sustained improvement in physical function, structural damage, and signs and symptom through 2 years in rheumatoid arthritis patients treated with infliximab (Remicade) and methotrexate. Arthritis Rheum. (in the press).
Charles, P. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521–1528 (1999).
Taylor, P.C. et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38–47 (2000).
Paleolog, E.M. et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258–1265 (1998).
Day, R. Adverse reactions to TNFα inhibitors in rheumatoid arthritis. Lancet 359, 540–541 (2002).
Arend, W.P. & Dayer, J.-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38, 151–160 (1995).
Nishimoto, N. et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426–1435 (2003).
Feldmann, M. & Maini, R.N. Anti-TNFα therapy or rheumatoid arthritis: What have we learned? Annu. Rev. Immunol. 19, 163–196 (2001).
van Dullemen, H.M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135 (1995).
Acknowledgements
Receiving a prize such as this promotes reflection. We could not have done this work without the highly productive and enjoyable association with each other over 20 years, and enormous support from many directions. We thank our families and wives (Tania and Geraldine), our assistants and our local and international scientific and clinical colleagues: those named in the text and, in particular, F. Breedveld, J. Kalden, J. Smolen, E. Paleolog, P. Charles, M. Elliott, P. Taylor; our clinical trial collaborators; research nurses; and collaborators at Centocor, in particular J. Woody, H. Weissman, J. Ghrayeb and T. Schaible. Most importantly, this could not have been accomplished without extensive financial support, which for us has been dominated by the British charities supporting arthritis research, arc (Arthritis Research Campaign) and the Kennedy Institute of Rheumatology Trust.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feldmann, M., Maini, R. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9, 1245–1250 (2003). https://doi.org/10.1038/nm939
Issue Date:
DOI: https://doi.org/10.1038/nm939
This article is cited by
-
Synthesis and applications of mirror-image proteins
Nature Reviews Chemistry (2023)
-
25 years of biologic DMARDs in rheumatology
Nature Reviews Rheumatology (2023)
-
Are TNF inhibitors still the agent of choice for RA?
Nature Reviews Rheumatology (2023)
-
A transformer-based model to predict peptide–HLA class I binding and optimize mutated peptides for vaccine design
Nature Machine Intelligence (2022)
-
Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential
Cellular and Molecular Life Sciences (2022)